FIELD: medicine; oncology.
SUBSTANCE: present group of inventions relates to medicine, namely to oncology, and concerns the combination therapy of lymphoma. To do this, phosphatidylinositol 3-kinase duvesilib inhibitor in combination with XP01 selinexor inhibitor or in combination with checkpoint PD-1 inhibitor is injected.
EFFECT: invention provides for the effective treatment of lymphoma due to the synergetic antitumor effect of combination components.
35 cl, 2 ex, 1 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
| SYNERGISTIC COMBINATIONS OF AURISTANE | 2015 |
|
RU2717570C2 |
| COMBINATION THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR TREATMENT OF CANCER | 2016 |
|
RU2786570C2 |
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
| IMPROVED THERAPEUTIC INDEX OF INHIBITORS AGAINST IMMUNE CHECKPOINT USING COMBINATION THERAPY INCLUDING PHY906 EXTRACT, SCUTELLARIA BAICALENSIS GEORGI (S) EXTRACT OR COMPOUND OF SUCH EXTRACTS | 2017 |
|
RU2753523C2 |
| METHOD OF TREATING CERVICAL CANCER | 2021 |
|
RU2832963C2 |
| COMBINATION THERAPY | 2013 |
|
RU2677245C2 |
| METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES | 2012 |
|
RU2626883C2 |
